Wecome Pharmaceutical Co Ltd (300878) — Working Capital to Net Assets Ratio
Wecome Pharmaceutical Co Ltd (300878) has a Working Capital to Net Assets ratio of 29.6% as of September 2025. Working capital of CN¥305.01 Million (current assets of CN¥533.01 Million minus current liabilities of CN¥228.01 Million) is measured against net assets of CN¥1.03 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300878 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Wecome Pharmaceutical Co Ltd Working Capital to Net Assets (2013–2024)
This chart shows how Wecome Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 29.6%, reflecting working capital of CN¥305.01 Million against net assets of CN¥1.03 Billion CNY. See 300878 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Wecome Pharmaceutical Co Ltd (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Wecome Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Wecome Pharmaceutical Co Ltd worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 32.0% | CN¥376.10 Million | CN¥1.17 Billion | CN¥616.48 Million | CN¥240.38 Million | ▼ -9.8 pp |
| 2023 | 41.9% | CN¥589.21 Million | CN¥1.41 Billion | CN¥1.03 Billion | CN¥445.55 Million | ▲ +7.4 pp |
| 2022 | 34.5% | CN¥486.32 Million | CN¥1.41 Billion | CN¥899.32 Million | CN¥413.00 Million | ▼ -10.8 pp |
| 2021 | 45.3% | CN¥637.69 Million | CN¥1.41 Billion | CN¥870.09 Million | CN¥232.40 Million | ▼ -11.4 pp |
| 2020 | 56.7% | CN¥784.97 Million | CN¥1.38 Billion | CN¥998.62 Million | CN¥213.65 Million | ▲ +8.4 pp |
| 2019 | 48.3% | CN¥251.27 Million | CN¥519.84 Million | CN¥440.94 Million | CN¥189.67 Million | ▲ +11.9 pp |
| 2018 | 36.4% | CN¥143.48 Million | CN¥393.83 Million | CN¥323.92 Million | CN¥180.45 Million | ▼ -9.8 pp |
| 2017 | 46.3% | CN¥141.64 Million | CN¥306.05 Million | CN¥303.43 Million | CN¥161.79 Million | ▼ -2.9 pp |
| 2016 | 49.2% | CN¥103.68 Million | CN¥210.90 Million | CN¥178.90 Million | CN¥75.22 Million | ▲ +6.3 pp |
| 2015 | 42.9% | CN¥55.76 Million | CN¥130.04 Million | CN¥114.19 Million | CN¥58.44 Million | ▲ +11.8 pp |
| 2014 | 31.1% | CN¥24.29 Million | CN¥78.22 Million | CN¥87.82 Million | CN¥63.52 Million | ▲ +17.3 pp |
| 2013 | 13.7% | CN¥4.72 Million | CN¥34.35 Million | CN¥65.93 Million | CN¥61.21 Million | — |